Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label single-arm study of etrasimod in pediatric ulcerative colitis
jRCT2071260002Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- Feb 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of etrasimod in autoimmune colitis, sponsored by Pfizer. Primary endpoint: Clinical remission based on Modified Mayo Score at Week 52. Started Feb 2026; status: recruiting.
02
Drugs
etrasimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2071260002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260002.